PTC (NASDAQ: PTC) will release its fiscal 2026 first quarter and on Wednesday, February 4 th after the stock market closes.

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...

Conference draws participants from more than 60 countries; demand for leadership programs reaches capacity From sold ...

PTC Therapeutics is keeping its regulatory teams busy. In its third-quarter results, the biotech reported pushback against its plans to seek approval for two molecules based on existing data—and saw ...

PTC (NASDAQ: PTC) today announced new artificial intelligence (AI) capabilities for its FlexPLM® retail product lifecycle ...

Founded in 1985, the Boston, Massachusetts-based PTC Inc. (PTC) provides software solutions and services globally that aid ...

Shares of PTC Inc. PTC shed 1.18% to $171.52 Friday, on what proved to be an all-around great trading session for the stock ...

Four months after Europe's drug reviewers doubled down and recommended the withdrawal of PTC Therapeutics' Translarna for lack of efficacy, the drug's regulatory odyssey is taking yet another turn.

PTC Inc. (PTC) shares ended the last trading session 17.6% higher at $210.47. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

PTC's solutions are helping enable a digital revolution in manufacturing, and its long-term growth looks assured. Management's guidance means PTC's growth will be heavily weighted to the second half ...